Patents by Inventor Orit Foord

Orit Foord has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
    Publication number: 20190077876
    Abstract: Provided herein are novel anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Application
    Filed: August 20, 2018
    Publication date: March 14, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: Marianne SANTAGUIDA, Monette AUJAY, Laura SAUNDERS, David LIU, Orit FOORD, Robert A. STULL, Paul Anthony ESCARPE
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20190046656
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 14, 2019
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 10137204
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 27, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 10118968
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: November 6, 2018
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • Anti-CD324 monoclonal antibodies and uses thereof
    Patent number: 10087258
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: October 2, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Monette Aujay, Orit Foord, Alex Bankovich, Johannes Hampl, Scott J. Dylla, David Liu
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20180237512
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: JOHANNES HAMPL, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL
  • Anti-claudin antibodies and methods of use
    Patent number: 10053511
    Abstract: Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 21, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Marianne Santaguida, Monette Aujay, Laura Saunders, David Liu, Orit Foord, Robert A. Stull, Paul Anthony Escarpe
  • High affinity human antibodies to human cytomegalovirus (CMV) gB protein
    Patent number: 10030069
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 24, 2018
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • Modulators and methods of use
    Patent number: 10017565
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 10, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Scott J. Dylla, Orit Foord, Robert A. Stull, Wade C. Anderson, Saiyou Ohshima
  • NOVEL MODULATORS AND METHODS OF USE
    Publication number: 20180162952
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ORIT FOORD, SCOTT J. DYLLA, ROBERT A. STULL, ALEX BANKOVICH, ALEXANDRA LEIDA LIANA LAZETIC, JEFFREY BERNSTEIN
  • Modulators and methods of use
    Patent number: 9969798
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: May 15, 2018
    Assignee: AbbVie Stemcentrx LLP
    Inventors: Johannes Hampl, Scott J. Dylla, Orit Foord, Robert A. Stull
  • Anti-DLL3 antibody drug conjugates and methods of use
    Patent number: 9937268
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 10, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9931421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 3, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of making DLL3 antibody drug conjugates
    Patent number: 9931420
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 3, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • PTK7 modulators and methods of use
    Patent number: 9914784
    Abstract: PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 13, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
  • METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20180036422
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20180036421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9878053
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 30, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180015178
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: January 18, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9867887
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: January 16, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao